• Publications
  • Influence
Population pharmacokinetics of dabrafenib, a BRAF inhibitor: Effect of dose, time, covariates, and relationship with its metabolites
Dabrafenib is a BRAF kinase inhibitor indicated for the treatment of BRAF V600E mutation‐positive melanoma. The population pharmacokinetics of dabrafenib, including changes over time and relevantExpand
  • 39
  • 5
Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma
AbstractPurpose To characterize the pharmacokinetics of oral trametinib, a first in class MEK inhibitor, identify covariates, and describe the relationship between exposure and clinical effects inExpand
  • 19
  • 1
Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours.
AIMS The aim of this phase 1, single centre, open label study in four patients with solid tumours was to determine the absolute bioavailability of a 2 mg oral dose of trametinib. Trametinib is anExpand
  • 27
  • 1
Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules
PurposeThere are several reasons why combining an inhibitor of the vascular endothelial and the platelet-derived growth factor receptor with a taxane might induce synergistic antitumor activity. ThisExpand
  • 18
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors
Purpose This study aimed to determine the safety, tolerability, and recommended phase II doses of trametinib plus uprosertib (GSK2141795) in patients with solid tumors likely to be sensitive to MEKExpand
  • 1
Indinavir Increases Midazolam N-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach
Midazolam is a widely used index substrate for assessing effects of xenobiotics on CYP3A activity. A previous study involving human hepatocytes showed the primary route of midazolam metabolism,Expand
Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects.
STUDY OBJECTIVE To evaluate factors affecting variability in response to remimazolam in general anesthesia. DESIGN Plasma concentration-time data from 11 Phase 1-3 clinical trials were pooled forExpand
Table of Contents